Everest Medicines launches first-of-its-kind IgA nephropathy treatment Nefecon® in China.
Everest Medicines has launched Nefecon® in China, a delayed-release capsule designed for IgA nephropathy (IgAN) patients. With the highest prevalence of primary glomerular diseases worldwide, China has a significant unmet medical need for effective treatments for IgAN patients. Nefecon® addresses this need, as it specifically targets the origin of IgAN, and is the first approved treatment of its kind in China.
May 14, 2024
3 Articles